Eli Lilly and Novo Nordisk, whose weight loss-related drugs have created a frenzy, are working with the Trump administration on a deal that would cut the cost of the lowest doses of their popular drugs to $149 for a month's supply, sources familiar with the matter told The Wall Street Journal. As part of the deal, which could be announced as soon as Thursday, the drugs would be sold through TrumpRx, a forthcoming government-run initiative expected to launch next year that will connect consumers directly with drug manufacturers to purchase discounted prescription drugs without insurance.Under t...
HALO NEWSLETTER
Join HALO today and unlock this story instantly — It's Free